Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 4/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100577 | 0.94 | KCNN4 (0.36) | KCNN4P2RX7JAK2ADORA2AADORA1 | |
| SCHEMBL10100762 | 0.88 | FYN (0.42) | KCNN4P2RX7ADORA2AADORA1FYN | |
| SCHEMBL10100765 | 0.87 | FYN (0.45) | KCNN4P2RX7FYNKIT | |
| SCHEMBL10100780 | 0.87 | KCNN4 (0.42) | KCNN4P2RX7FYN | |
| SCHEMBL10100758 | 0.86 | LRRK2 (0.37) | KCNN4JAK2PDGFRBFGFR1SRC | |
| SCHEMBL10100763 | 0.86 | KCNN4 (0.32) | KCNN4P2RX7KITKDRFLT3 | |
| SCHEMBL10100760 | 0.85 | LRRK2 (0.36) | KCNN4JAK2PDGFRBFGFR1SRC | |
| SCHEMBL10100716 | 0.85 | ABL1 (0.36) | KCNN4SRCKDR | |
| SCHEMBL10100761 | 0.84 | JAK2 (0.36) | KCNN4JAK2KDR | |
| SCHEMBL10100748 | 0.83 | ALK (0.39) | P2RX7KITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | KCNN4 4066/4885P2RX7 4285/4885JAK2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.